Research Communications in Molecular Pathology and Pharmacology 1995-02-01

Stimulatory effect of perhexiline maleate on the basal and LHRH-stimulated luteinizing hormone release from rat pituitary cell aggregates in vitro.

V Shacoori, B Saiag, A Girre, B Rault

Index: Res. Commun. Mol. Pathol. Pharmacol. 87(2) , 115-23, (1995)

Full Text: HTML

Abstract

Perhexiline maleate (PM) is an anti-anginal agent of amphiphilic character involved in lipidosis disorders. Experiments were carried out to study PM action on LH release from rat anterior pituitary cell aggregates. PM caused significant and dose-dependent increases of basal LH release when the aggregates had been previously treated with PM for 20 min, then incubated for 30 min with the same concentration of drug after renewal of the culture medium. The increases of basal LH secretion induced by PM were 69% (p < 0.001) at a concentration of 10(-7)M, 130% (p < 0.001) at a concentration of 10(-5)M and 250% (p < 0.001) at a concentration of 10(-4)M. PM also increased the LHRH-stimulated LH release by 25.5% (p < 0.05) at a concentration of 10(-5)M and by 74.5% (p < 0.01) at the concentration of 10(-4)M. The results showed that PM was more potent on basal LH release than on LH stimulated by LHRH. The mechanism of this action remains unclear. It may be due to the lipidosis property of the drug.


Related Compounds

Related Articles:

Torsade de pointes associated with perhexiline maleate therapy.

1990-12-01

[Aust. N. Z. J. Med. 20(6) , 818-20, (1990)]

Further studies on the pharmacokinetics of perhexiline maleate in humans.

1986-01-01

[Xenobiotica 16(1) , 63-8, (1986)]

A case series of concomitant treatment of perhexiline with amiodarone.

2012-04-01

[Ther. Drug Monit. 34(2) , 227-31, (2012)]

Impairment of sulfobromophthalein biliary excretion and inhibition of glutathione S-transferase activity induced by perhexiline maleate in rats.

1988-09-15

[Biochem. Pharmacol. 37(18) , 3461-5, (1988)]

Interactions of perhexiline maleate and arylalkylamine derivatives with cytochrome P-450 and in-vitro hydroxylation.

1986-07-15

[Biochem. Pharmacol. 35(14) , 2301-7, (1986)]

More Articles...